Background : Nowadays obesity has increased dramatically in developed countries which lead various metabolic disorders such as type 2 diabetes, hypertension, cancer, and the risk of stroke. Thus, looking forward a new chemical entity from natural sources which have a strong potential of anti-lipid regulation activity. Recently, protein based nanomedicine offers a new approach to treat a number of diseases including metabolic disorder such as obesity. In this study we evaluated the anti-lipid regulation effect of nano-carrier Bovine serum albumin and Mesoporous silica (MSNPs) conjugated ginsenoside F1 in 3T3-L1adipocytes and HepG2 hepatocytes. Methods and Results : BSA incorporated drugs has been shown to protect the drug degredation as well as improvement bioavalilability. To assess the anti- adipogenic effect of BSA-F1 and MSNPs-F1 cell viability was investigated in different time point of cell cycle growth and the intracellular lipid accumulation was evaluated in mature adipocytes and hepatocytes by Oil red staining assay. In addition, transcriptional gene regulation was quantified by the real time PCR for targeting adipogenic genes such as PPARγ, STAT3, CEBPα, ap2 and aP2 as well as hepatogenic genes such as ACC, AMPK, FAS and PPARα. Moreover, protein expression was evaluated by immunoblotting assay. Conclusion : Altogether, the above results were confirmed that BSA-F1 at dose 25 μM exhibited the anti-adipogenesis effect by downregulating the major transcriptional factors PPAR γ/STAT3 in signalling in 3T3-L1 mature adipocytes and upregulated the fatty acid oxidative AMPK signaling in fatty acid induced HepG2 hepatocytes.